Literature DB >> 8304553

High-flow microinfusion: tissue penetration and pharmacodynamics.

P F Morrison1, D W Laske, H Bobo, E H Oldfield, R L Dedrick.   

Abstract

High-flow microinfusion provides a means for delivering macromolecules to large volumes of brain in easily obtainable time intervals. Slowly degraded approximately 180-kDa macromolecules, delivered at a constant volumetric flow rate of 3 microliters/min into homogeneous brain tissue (e.g., gray matter), would penetrate to a 1.5-cm radius in 12 h. The predicted concentration profile is relatively flat until it declines precipitously at the flow front. Hence, tissues are dosed rather uniformly, providing control over the undesired toxicity that may occur with alternative methods that depend on large concentration gradients for tissue transport. The penetration advantage of high-flow (convective) over low-flow (diffusive) microinfusion has been assessed at fixed pharmacodynamic effect. A 12-h high-flow microinfusion of a macromolecule degraded with a characteristic time of 33.5 h would provide 5- to 10-fold increases in volume over low-flow infusion and total treatment volumes > 10 cm3. Slower degradation rates would result in larger treatment volumes; more rapid degradation rates would reduce the volume but still favor convective over diffusive administration. This technique may be applicable to a variety of diagnostic and therapeutic agents such as radioimmunoconjugates, immunotoxins, enzymes, growth factors, and oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8304553     DOI: 10.1152/ajpregu.1994.266.1.R292

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  95 in total

1.  Changes in brain cell shape create residual extracellular space volume and explain tortuosity behavior during osmotic challenge.

Authors:  K C Chen; C Nicholson
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

2.  Convection-enhanced delivery catheter placements for high-grade gliomas: complications and pitfalls.

Authors:  Tal Shahar; Zvi Ram; Andrew A Kanner
Journal:  J Neurooncol       Date:  2011-11-04       Impact factor: 4.130

3.  Dynamic contrast-enhanced MRI of Gd-albumin delivery to the rat hippocampus in vivo by convection-enhanced delivery.

Authors:  Jung Hwan Kim; Garrett W Astary; Tatiana L Nobrega; Svetlana Kantorovich; Paul R Carney; Thomas H Mareci; Malisa Sarntinoranont
Journal:  J Neurosci Methods       Date:  2012-06-08       Impact factor: 2.390

4.  Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38.

Authors:  Neal Luther; Nai-Kong Cheung; Eleni P Souliopoulos; Ioannis Karampelas; Ioannis Karempelas; Daniel Bassiri; Mark A Edgar; Hong-Fen Guo; Ira Pastan; Philip H Gutin; Mark M Souweidane
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

5.  EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma.

Authors:  Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao
Journal:  Cancer Res       Date:  2010-07-20       Impact factor: 12.701

Review 6.  Real-time imaging and quantification of brain delivery of liposomes.

Authors:  Michal T Krauze; John Forsayeth; John W Park; Krystof S Bankiewicz
Journal:  Pharm Res       Date:  2006-09-14       Impact factor: 4.200

7.  A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers.

Authors:  Raghu Raghavan; Roger W Howell; Michael R Zalutsky
Journal:  Biomed Phys Eng Express       Date:  2017-05-05

8.  The potential of theragnostic ¹²⁴I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma.

Authors:  Neal Luther; Zhiping Zhou; Pat Zanzonico; Nai-Kong Cheung; John Humm; Mark A Edgar; Mark M Souweidane
Journal:  Neuro Oncol       Date:  2014-02-12       Impact factor: 12.300

9.  Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model.

Authors:  J Pollina; R J Plunkett; M J Ciesielski; A Lis; T A Barone; S J Greenberg; R A Fenstermaker
Journal:  J Neurooncol       Date:  1998-09       Impact factor: 4.130

10.  Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft.

Authors:  Emilie Allard; Delphine Jarnet; Anne Vessières; Sandrine Vinchon-Petit; Gérard Jaouen; Jean-Pierre Benoit; Catherine Passirani
Journal:  Pharm Res       Date:  2009-11-12       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.